Fate and Transformation of a Conjugated Natural Hormone
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Antiestrogenic Action of Dihydrotestosterone in Mouse Breast
Antiestrogenic action of dihydrotestosterone in mouse breast. Competition with estradiol for binding to the estrogen receptor. R W Casey, J D Wilson J Clin Invest. 1984;74(6):2272-2278. https://doi.org/10.1172/JCI111654. Research Article Feminization in men occurs when the effective ratio of androgen to estrogen is lowered. Since sufficient estrogen is produced in normal men to induce breast enlargement in the absence of adequate amounts of circulating androgens, it has been generally assumed that androgens exert an antiestrogenic action to prevent feminization in normal men. We examined the mechanisms of this effect of androgens in the mouse breast. Administration of estradiol via silastic implants to castrated virgin CBA/J female mice results in a doubling in dry weight and DNA content of the breast. The effect of estradiol can be inhibited by implantation of 17 beta-hydroxy-5 alpha-androstan-3-one (dihydrotestosterone), whereas dihydrotestosterone alone had no effect on breast growth. Estradiol administration also enhances the level of progesterone receptor in mouse breast. Within 4 d of castration, the progesterone receptor virtually disappears and estradiol treatment causes a twofold increase above the level in intact animals. Dihydrotestosterone does not compete for binding to the progesterone receptor, but it does inhibit estrogen-mediated increases of progesterone receptor content of breast tissue cytosol from both control mice and mice with X-linked testicular feminization (tfm)/Y. Since tfm/Y mice lack a functional androgen receptor, we conclude that this antiestrogenic action of androgen is not mediated by the androgen receptor. Dihydrotestosterone competes with estradiol for binding to the cytosolic estrogen receptor of mouse breast, […] Find the latest version: https://jci.me/111654/pdf Antiestrogenic Action of Dihydrotestosterone in Mouse Breast Competition with Estradiol for Binding to the Estrogen Receptor Richard W. -
Degradation and Metabolite Formation of Estrogen Conjugates in an Agricultural Soil
Journal of Pharmaceutical and Biomedical Analysis 145 (2017) 634–640 Contents lists available at ScienceDirect Journal of Pharmaceutical and Biomedical Analysis j ournal homepage: www.elsevier.com/locate/jpba Degradation and metabolite formation of estrogen conjugates in an agricultural soil a,b b,∗ Li Ma , Scott R. Yates a Department of Environmental Sciences, University of California, Riverside, CA 92521, United States b Contaminant Fate and Transport Unit, U.S. Salinity Laboratory, Agricultural Research Service, United States Department of Agriculture, Riverside, CA 92507, United States a r t i c l e i n f o a b s t r a c t Article history: Estrogen conjugates are precursors of free estrogens such as 17ß-estradiol (E2) and estrone (E1), which Received 10 April 2017 cause potent endocrine disrupting effects on aquatic organisms. In this study, microcosm laboratory Received in revised form 11 July 2017 ◦ experiments were conducted at 25 C in an agricultural soil to investigate the aerobic degradation and Accepted 31 July 2017 metabolite formation kinetics of 17ß-estradiol-3-glucuronide (E2-3G) and 17ß-estradiol-3-sulfate (E2- Available online 1 August 2017 3S). The aerobic degradation of E2-3G and E2-3S followed first-order kinetics and the degradation rates were inversely related to their initial concentrations. The degradation of E2-3G and E2-3S was extraordi- Keywords: narily rapid with half of mass lost within hours. Considerable quantities of E2-3G (7.68 ng/g) and E2-3S Aerobic degradation 17ß-estradiol-3-glucuronide (4.84 ng/g) were detected at the end of the 20-d experiment, particularly for high initial concentrations. -
Total Estradiol and Total Testosterone
Laboratory Procedure Manual Analyte: Total Estradiol and Total Testosterone Matrix: Serum Method: Simultaneous Measurement of Estradiol and Testosterone in Human Serum by ID LC-MS/MS Method No: 1033 Revised: as performed by: Clinical Chemistry Branch Division of Laboratory Sciences National Center for Environmental Health contact: Dr. Hubert W. Vesper Phone: 770-488-4191 Fax: 404-638-5393 Email: [email protected] James Pirkle, M.D., Ph.D. Division of Laboratory Sciences Important Information for Users CDC periodically refines these laboratory methods. It is the responsibility of the user to contact the person listed on the title page of each write-up before using the analytical method to find out whether any changes have been made and what revisions, if any, have been incorporated. Total Estradiol and Total Testosterone NHANES 2015-16 Public Release Data Set Information This document details the Lab Protocol for testing the items listed in the following table for SAS file TST_I: VARIABLE NAME SAS LABEL (and SI units) LBXTST Testosterone, total (nmol/L) LBXEST Estradiol (pg/mL) 1 of 49 Total Estradiol and Total Testosterone NHANES 2015-16 Contents 1 Summary of Test Principle and Clinical Relevance 7 1.1 Intended Use 7 1.2 Clinical and Public Health Relevance 7 1.3 Test Principle 8 2 Safety Precautions 10 2.1 General Safety 10 2.2 Chemical Hazards 10 2.3 Radioactive Hazards 11 2.4 Mechanical Hazards 11 2.5 Waste Disposal 11 2.6 Training 11 3 Computerization and Data-System Management 13 3.1 Software and Knowledge Requirements 13 3.2 Sample Information 13 3.3 Data Maintenance 13 3.4 Information Security 13 4 Preparation for Reagents, Calibration Materials, Control Materials, and All Other Materials; Equipment and Instrumentation. -
Estrogen Pharmacology. I. the Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man
Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man Mark N. Mueller, Attallah Kappas J Clin Invest. 1964;43(10):1905-1914. https://doi.org/10.1172/JCI105064. Research Article Find the latest version: https://jci.me/105064/pdf Journal of Clinical Investigation Vol. 43, No. 10, 1964 Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) inMan* MARK N. MUELLER t AND ATTALLAH KAPPAS + WITH THE TECHNICAL ASSISTANCE OF EVELYN DAMGAARD (From the Department of Medicine and the Argonne Cancer Research Hospital,§ the University of Chicago, Chicago, Ill.) This report 1 describes the influence of natural biological action of natural estrogens in man, fur- estrogens on liver function, with special reference ther substantiate the role of the liver as a site of to sulfobromophthalein (BSP) excretion, in man. action of these hormones (5), and probably ac- Pharmacological amounts of the hormone estradiol count, in part, for the impairment of BSP dis- consistently induced alterations in BSP disposal posal that characterizes pregnancy (6) and the that were shown, through the techniques of neonatal period (7-10). Wheeler and associates (2, 3), to result from profound depression of the hepatic secretory Methods dye. Chro- transport maximum (Tm) for the Steroid solutions were prepared by dissolving crystal- matographic analysis of plasma BSP components line estradiol and estriol in a solvent vehicle containing revealed increased amounts of BSP conjugates 10% N,NDMA (N,N-dimethylacetamide) 3 in propylene during estrogen as compared with control pe- glycol. Estradiol was soluble in a concentration of 100 riods, implying a hormonal effect on cellular proc- mg per ml; estriol, in a concentration of 20 mg per ml. -
Neurosteroid Metabolism in the Human Brain
European Journal of Endocrinology (2001) 145 669±679 ISSN 0804-4643 REVIEW Neurosteroid metabolism in the human brain Birgit Stoffel-Wagner Department of Clinical Biochemistry, University of Bonn, 53127 Bonn, Germany (Correspondence should be addressed to Birgit Stoffel-Wagner, Institut fuÈr Klinische Biochemie, Universitaet Bonn, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany; Email: [email protected]) Abstract This review summarizes the current knowledge of the biosynthesis of neurosteroids in the human brain, the enzymes mediating these reactions, their localization and the putative effects of neurosteroids. Molecular biological and biochemical studies have now ®rmly established the presence of the steroidogenic enzymes cytochrome P450 cholesterol side-chain cleavage (P450SCC), aromatase, 5a-reductase, 3a-hydroxysteroid dehydrogenase and 17b-hydroxysteroid dehydrogenase in human brain. The functions attributed to speci®c neurosteroids include modulation of g-aminobutyric acid A (GABAA), N-methyl-d-aspartate (NMDA), nicotinic, muscarinic, serotonin (5-HT3), kainate, glycine and sigma receptors, neuroprotection and induction of neurite outgrowth, dendritic spines and synaptogenesis. The ®rst clinical investigations in humans produced evidence for an involvement of neuroactive steroids in conditions such as fatigue during pregnancy, premenstrual syndrome, post partum depression, catamenial epilepsy, depressive disorders and dementia disorders. Better knowledge of the biochemical pathways of neurosteroidogenesis and -
Convergence of Multiple Mechanisms of Steroid Hormone Action
Review 569 Convergence of Multiple Mechanisms of Steroid Hormone Action Authors S. K. Mani 1 * , P. G. Mermelstein 2 * , M. J. Tetel 3 * , G. Anesetti 4 * Affi liations 1 Department of Molecular & Cellular Biology and Neuroscience, Baylor College of Medicine, Houston, TX, USA 2 Department of Neuroscience, University of Minnesota, Minneapolis, MN, USA 3 Neuroscience Program, Wellesley College, Wellesley, MA, USA 4 Departamento de Hostologia y Embriologia, Facultad de Medicine, Universidad de la Republica, Montevideo, Uruguay Key words Abstract receptors can also be activated in a “ligand-inde- ● ▶ estrogen ▼ pendent” manner by other factors including neu- ● ▶ progesterone Steroid hormones modulate a wide array of rotransmitters. Recent studies indicate that rapid, ▶ ● signaling physiological processes including development, nonclassical steroid eff ects involve extranuclear ● ▶ cross-talk metabolism, and reproduction in various species. steroid receptors located at the membrane, which ● ▶ ovary ● ▶ brain It is generally believed that these biological eff ects interact with cytoplasmic kinase signaling mol- are predominantly mediated by their binding to ecules and G-proteins. The current review deals specifi c intracellular receptors resulting in con- with various mechanisms that function together formational change, dimerization, and recruit- in an integrated manner to promote hormone- ment of coregulators for transcription-dependent dependent actions on the central and sympathetic genomic actions (classical mechanism). In addi- nervous systems. tion, to their cognate ligands, intracellular steroid Abbreviations gene expression and function. Interestingly, not ▼ all the “classical” receptors are intranuclear and CBP CREB binding protein can be associated at the membrane. As described CRE CREB response element in this review, extranuclear ERs and PRs at the DAR Dopamine receptor (DAR) membrane or in the cytoplasm can interact with ER Estrogen receptor G proteins and signaling kinases, and other G received 13 . -
Pharmacology/Therapeutics II Block III Lectures 2013-14
Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine -
Studies on Phenolic Steroids in Human Subjects. VII. Metabolic Fate of Estriol and Its Glucuronide
Studies on Phenolic Steroids in Human Subjects. VII. Metabolic Fate of Estriol and Its Glucuronide Avery A. Sandberg, W. Roy Slaunwhite Jr. J Clin Invest. 1965;44(4):694-702. https://doi.org/10.1172/JCI105181. Research Article Find the latest version: https://jci.me/105181/pdf Journal of Clinical Investigation Vol. 44, No. 4, 1965 Studies on Phenolic Steroids in Human Subjects. VII. Metabolic Fate of Estriol and Its Glucuronide * AVERY A. SANDBERG t AND W. RoY SLAUNWHITE, JR. (From the Roswell Park Memorial Institute, Buffalo, N. Y.) Estriol has been considered a metabolic product of enzymes capable of oxidizing the hydroxyl of the more active estrogens, estrone (1, 2) and group at position 16, a finding not reported in the indirectly estradiol. Recently, an alternative path- past. way has been proposed (3) based on the observa- The attention of investigators has recently been tions that 16a-hydroxydehydroepiandrosterone is directed toward steroid conjugates, not only be- present in high concentrations in cord blood and cause they are excreted in that form, but owing to that it is aromatized by placental enzymes. During the demonstration that steroid sulfates may, in pregnancy the placenta has been thought the some instances, serve as biosynthetic intermediates source of the mother's urinary estriol, but recent (12-14), that dehydroepiandrosterone sulfate is evidence indicates that the fetus (4-6) and, in par- secreted by the adrenal cortex (15), that estrone ticular, the fetal liver (7) may play an important circulates in the blood as a sulfate (16), and that role in the conversion of the estrone to estriol steroid sulfates appear to be biologically active (8). -
Dehydroepiandrosterone an Inexpensive Steroid Hormone That Decreases the Mortality Due to Sepsis Following Trauma-Induced Hemorrhage
PAPER Dehydroepiandrosterone An Inexpensive Steroid Hormone That Decreases the Mortality Due to Sepsis Following Trauma-Induced Hemorrhage Martin K. Angele, MD; Robert A. Catania, MD; Alfred Ayala, PhD; William G. Cioffi, MD; Kirby I. Bland, MD; Irshad H. Chaudry, PhD Background: Recent studies suggest that male sex ste- hemorrhage and resuscitation, the animals were killed roids play a role in producing immunodepression follow- and blood, spleens, and peritoneal macrophages were har- ing trauma-hemorrhage. This notion is supported by stud- vested. Splenocyte proliferation and interleukin (IL) 2 ies showing that castration of male mice before trauma- release and splenic and peritoneal macrophage IL-1 and hemorrhage or the administration of the androgen receptor IL-6 release were determined. In a separate set of experi- blocker flutamide following trauma-hemorrhage in non- ments, sepsis was induced by cecal ligation and punc- castrated animals prevents immunodepression and im- ture at 48 hours after trauma-hemorrhage and resusci- proves the survival rate of animals subjected to subse- tation. For those studies, the animals received vehicle, a quent sepsis. However, it remains unknown whether the single 100-µg dose of DHEA, or 100 µg/d DHEA for 3 most abundant steroid hormone, dehydroepiandros- days following hemorrhage and resuscitation. Survival terone (DHEA), protects or depresses immune functions was monitored for 10 days after the induction of sepsis. following trauma-hemorrhage. In this regard, DHEA has been reported to have estrogenic and androgenic proper- Results: Administration of DHEA restored the de- ties, depending on the hormonal milieu. pressed splenocyte and macrophage functions at 24 hours after trauma-hemorrhage. -
Low Testosterone (Hypogonadism)
Low Testosterone (Hypogonadism) Testosterone is an anabolic-androgenic steroid hormone which is made in the testes in males (a minimal amount is also made in the adrenal glands). Testosterone has two major functions in the human body. Testosterone production is regulated by hormones released from the brain. The brain and testes work together to keep testosterone in the normal range (between 199 ng/dL and 1586 ng/dL) Testosterone is needed to form and maintain the male sex organs, regulate sex drive (libido) and promote secondary male sex characteristics such as voice deepening and development of facial and body hair. Testosterone facilitates muscle growth as well as bone development and maintenance. Low testosterone levels in the blood are seen in males with a medical condition known as Hypogonadism. This may be due to a signaling problem between the brain and testes that can cause production to slow or stop. Hypogonadism can also be caused by a problem with production in the testes themselves. Causes Primary: This type of hypogonadism — also known as primary testicular failure — originates from a problem in the testicles. Secondary: This type of hypogonadism indicates a problem in the hypothalamus or the pituitary gland — parts of the brain that signal the testicles to produce testosterone. The hypothalamus produces gonadotropin- releasing hormone, which signals the pituitary gland to make follicle-stimulating hormone (FSH) and luteinizing hormone. Luteinizing hormone then signals the testes to produce testosterone. Either type of hypogonadism may be caused by an inherited (congenital) trait or something that happens later in life (acquired), such as an injury or an infection. -
Feminizing Gender-Affirming Hormone Care the Michigan Medicine Approach
Feminizing Gender-Affirming Hormone Care The Michigan Medicine Approach Our goal is to partner with you to provide the medical care you need in affirming your gender. Our focus is on your lifelong health, safety, and individual medical and transition-related needs. The Michigan Medicine approach is based on the limited but growing medical evidence surrounding gender-affirming hormone care. Based on the available science, we believe mimicking normal physiology will provide you with the best balance of physical and emotional changes and long-term health. This philosophy aligns with current national and international medical guidelines in the care of gender diverse people. We are committed to staying up-to-date with the latest research and medical evidence to ensure you are getting the highest quality care. We know that there are competing approaches to gender-affirming care that are not based on validated scientific evidence. These approaches make scientifically unsubstantiated claims and have unknown short and long-term risks. We are happy to discuss these with you. Below are some answers to questions our patients have asked us about gender- affirming hormone care. We hope the Q&A will help you understand the medical evidence behind our approach to your gender-affirming hormone care, and how it may differ from other approaches, including the approach other well-known clinics in Southeast Michigan. Is there a benefit for monitoring both estrone (E1) and estradiol (E2) levels and aiming for a particular ratio? There are 3 naturally occurring human estrogens: estrone (E1), estradiol (E2), and estriol (E3). Your body naturally balances your estradiol and estrone ratio. -
Hormonal and Immunological Aspects of the Phylogeny of Sex Steroid
Proc. Nati. Acad. Sci. USA Vol. 77, No. 8, pp. 4578-4582, August 1980 Biochemistry Hormonal and immunological aspects of the phylogeny of sex steroid binding plasma protein (estradiol/dihydrotestosterone/a-fetoprotein) JACK-MICHEL RENOIR, CHRISTINE MERCIER-BODARD, AND ETIENNE-EMILE BAULIEU Unite de Recherches sur le Metabolisme Mol6culaire et la Physiopathologie des St6roides de l'Institut National de la Sante et de la Recherche MWdicale, (U 33), Universite Paris-Sud, DMpartement de Chimie Biologique, 78 rue du GUn6ral Leclerc, 94270 Bicetre, France Communicated by Seymour Lieberman, May 5,1980 ABSTRACT Sex steroid binding plasma protein (Sbp) in man acetate, 1:1 (vol/vol) for estradiol. Nonradioactive steroids were and in monkeys binds the androgens dihydrotestosterone and a gift of Roussel-Uclaf (Romainville) (guaranteed 99% testosterone and the estrogen estradiol with high affinity (Kd tO.5, 1, and 2 nM, respectively). Detailed studies of steroid pure). binding specificity give the same results in all primates, except Chemicals and Animals. Tubing [Visking-Nojax, 8/32 in. that in humans and chimpanzees estrone does not compete for (6.4 mm); from Union Carbide Corporation, New York] was dihydrotestosterone binding. In other mammals, Sbps of Arti- used in equilibrium dialyses. Agarose (Indubiose A 37) was odactyla and Lagomorpha have the same range of affinities for purchased from l'Industrie Biologique Francgaise (Paris), Ul- androgens but they do not bind estradiol to any significant ex- trogel AcA 34 was from LKB (Uppsala, Sweden), and Freund's tent (Kd >280 nM). The dog has an unusual Sbp (Kd for dihy- drotestosterone, 7.1 nM; for estiadiol, 125 nM), and rodents do complete and incomplete adjuvants were from Difco.